Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 2,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $45.92, for a total value of $91,840.00. Following the sale, the executive vice president now owns 116,071 shares in the company, valued at $5,329,980.32. The trade was a 1.69 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, January 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $49.32, for a total transaction of $98,640.00.
• On Tuesday, December 10th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.64, for a total transaction of $369,672.00.
• On Tuesday, November 26th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $50.16, for a total transaction of $366,168.00.
• On Tuesday, November 12th, Fady Ibraham Malik sold 6,342 shares of Cytokinetics stock. The stock was sold at an average price of $58.48, for a total value of $370,880.16.
• On Wednesday, October 30th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $51.91, for a total value of $378,943.00.

Cytokinetics Price Performance

Cytokinetics stock opened at $47.86 on Friday. The firm has a market cap of $5.65 billion, a PE ratio of -8.90 and a beta of 0.82. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The stock’s fifty day moving average price is $48.80 and its two-hundred day moving average price is $53.00. Cytokinetics, Incorporated has a one year low of $44.49 and a one year high of $84.11.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $1.21 million. During the same period in the previous year, the business posted ($1.35) earnings per share. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. As a group, research analysts expect that Cytokinetics, Incorporated will post -5.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on CYTK. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price objective on shares of Cytokinetics in a research report on Monday, December 2nd. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a report on Tuesday, January 14th. Royal Bank of Canada upped their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. Finally, Mizuho raised their price objective on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.40.

Hedge Funds Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. UMB Bank n.a. boosted its position in shares of Cytokinetics by 65.6% during the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 238 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 680 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Cytokinetics in the 3rd quarter valued at $54,000. Quarry LP raised its holdings in shares of Cytokinetics by 233.3% during the 2nd quarter. Quarry LP now owns 2,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,400 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of Cytokinetics during the 4th quarter worth $133,000.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.